Bullish case
$86 to $93
More likely if the growth portfolio compounds, iberdomide and mezigdomide launch well, Eliquis stays resilient, late-stage readouts are positive, and the market values BMY near 12x earnings.
Bristol Myers Squibb Company research snapshot
BMY AI Stock Analysis
BMY AI stock analysis currently reads Bristol Myers Squibb Company as a mature large-cap biopharma company whose transition into a growth-led portfolio is gaining traction. At the August 2, 2026 data cutoff, BMY closed at $65.31 on July 31, 2026, with an implied market capitalization of about $133.41 billion. The company beat second-quarter estimates, raised 2026 revenue and EPS guidance, and its growth portfolio now generates roughly 58% of total revenue, led by Eliquis, Reblozyl, Breyanzi, Camzyos, and Opdivo Qvantig. The stock sits just below its 52-week high of $65.66 with an overbought RSI near 71, so the deep-value discount that existed earlier in the year has narrowed. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$65.31
Market cap
$133.41 billion
AI score
70 / 100
Rating
Executing transition, growth portfolio now about 58% of revenue
Trend status
Uptrend intact, short-term overbought after earnings rally
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Bristol Myers Squibb has long public filings, a detailed Q2 2026 earnings release and 8-K, quarterly product revenue tables, an earnings call transcript, analyst coverage, and broad technical data.
- bias Check
- The main AI bias risk is accepting the raised-guidance and growth-portfolio narrative after the stock already rallied, while under-weighting Eliquis concentration, Medicare pricing pressure, legacy erosion, leverage, and binary clinical readouts.
- ai Confidence
- High for the Q2 2026 reported metrics, raised guidance, share-count math, valuation calculations, and technical snapshot. Medium for forward valuation because trial readouts, FDA decisions, patent disputes, and pricing policy can reprice the stock quickly.
- investment Certainty
- Medium. Execution and cash flow are measurable, but the stock has already moved close to the 52-week high, and the long-term thesis still depends on pipeline replacement power and disciplined capital allocation.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bristol Myers Squibb sells patented medicines in oncology, hematology, cardiovascular, immunology, and neuroscience, with a growth portfolio that now generates about 58% of revenue. | High |
| Moat | The moat comes from patents, clinical evidence, physician trust, payer access, regulatory expertise, global scale, and manufacturing know-how, and it narrows as exclusivity expires. | Medium-high |
| Management | Chris Boerner and the team delivered a Q2 beat, raised 2026 guidance, paid down about $1.2 billion of debt in the quarter, and kept business development disciplined. | Medium-high |
| Financial trend | Q2 2026 revenue rose 5% Ex-FX to $12.973 billion, non-GAAP EPS rose 40% to $2.04, and 2026 guidance was raised to about $49.0-50.0 billion revenue and $6.75-7.00 non-GAAP EPS. | High |
| Valuation | At $65.31, BMY trades near 9.5x the 2026 guidance midpoint, about 10.2x consensus forward EPS, 11.7x free cash flow, and a 3.86% dividend yield. | Medium-high |
| Technical trend | Price is above the 50-day and 200-day moving averages and near the 52-week high of $65.66, but the 14-day RSI near 71 is overbought. | Medium |
| Risk level | Main risks are Eliquis concentration and price pressure, Revlimid and Pomalyst erosion, Medicare negotiation, binary trial readouts, and about $31.7 billion of net debt. | Medium-high |
| AI confidence | High for descriptive research and audited calculations. Lower for exact price outcomes because pharma stocks can move sharply around trial and regulatory events. | High data confidence |
| Investment certainty | Medium. BMY is no longer deeply discounted after the rally, so the margin of safety now depends more on continued execution than on a beaten-down price. | Medium |
BMY AI stock forecast
BMY AI Stock Forecast Scenarios
The BMY AI stock forecast uses scenario math around the $65.31 quote and Bristol Myers Squibb 2026 non-GAAP EPS guidance midpoint of $6.875. The audited three-year framework produced a bearish area near $40-47, a base area near $62-68, and a bullish area near $86-93 before dividends.
Base case
$62 to $68
More likely if EPS holds near the 2026 guidance base, growth products offset most legacy erosion, and investors keep the stock near a 9.5-10x earnings multiple.
Bearish case
$40 to $47
More likely if Revlimid and other legacy declines accelerate, Eliquis pricing or competition worsens, pipeline assets disappoint, or leverage and patent risk drive the multiple toward 7-8x earnings.
BMY AI technical analysis
BMY AI Technical Analysis
BMY AI technical analysis is constructive but short-term extended as of the August 2, 2026 cutoff. StockAnalysis reported price at $65.31 at the July 31, 2026 close, a 50-day moving average near $58.12, a 200-day moving average near $55.57, and a 14-day RSI near 71.01. The stock sits just below its 52-week high of $65.66 after the July 30 Q2 earnings rally.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $65.31 | StockAnalysis close on July 31, 2026, used for market cap and valuation math. |
| 52-week high resistance | $65.66 | Intraday high on July 31, 2026; a close above it would open fresh upside. |
| Near support | $62.2 to $63.5 | The July 30 earnings-day low near $62.23 and recent daily lows form the nearest support band. |
| Secondary support | $60 to $61.5 | Mid-July consolidation zone that held before the earnings rally. |
| 50-day moving average | $58.12 | Price holds well above the 50-day average, supporting the medium-term uptrend. |
| 200-day moving average | $55.57 | The long-term average sits below the 50-day, consistent with an established uptrend. |
| Momentum | 14-day RSI 71.01 | RSI is in overbought territory after the rally, which raises pullback risk. |
| Volume | 20-day average about 10.8 million shares | Volume expanded to about 18 million shares on the July 30 earnings day. |
| Volatility | Low-beta pharma volatility | Beta was listed near 0.22, but drug-specific events can still cause sudden gaps. |
| Invalidation | Close below $62, then $58 | A decisive break below the earnings-day low and then the 50-day average would weaken the setup. A break below the 200-day average would be more serious. |
BMY AI trading strategy
BMY AI Trading Strategy Framework
The BMY AI trading strategy is a rules-based research framework for a large-cap biopharma stock in an improving transition. It is not personal advice and should be paired with live quotes, filings, position sizing, FDA and clinical event checks, and portfolio-level risk limits.
Trend-following setup
Watch for BMY to hold above $62 and the 50-day and 200-day moving averages, and to close above the $65.66 52-week high with volume confirmation.
A close below $62, or a failed breakout after a catalyst, should invalidate the short-term trend setup.
Mean-reversion setup
If BMY pulls back toward $60-62 without a product, trial, or guidance problem, compare the selloff with cash flow, dividend coverage, and growth portfolio evidence.
Do not average down without a defined loss limit because patent, pricing, and trial news can turn a support level into a thesis break.
Fundamental monitor
Track growth portfolio revenue, Eliquis growth and pricing, Revlimid erosion, non-GAAP EPS guidance, free cash flow, debt reduction, dividend coverage, and the iberdomide, mezigdomide, milvexian, admilparant, and Sotyktu lupus readouts.
Reduce confidence if EPS support comes mainly from cost cuts, adjustments, or multiple expansion rather than durable product-level revenue and cash flow.
Investment research summary
Four-master Research Compression
Business essence
Bristol Myers Squibb turns scientific discovery, clinical proof, regulatory approval, payer access, and global commercialization into recurring medicine revenue for serious diseases.
Moat
The moat is strongest where patents, clinical evidence, physician familiarity, reimbursement access, and scale reinforce one another. It narrows when exclusivity expires or rivals show better outcomes, safety, convenience, or price.
Munger risk inversion
The thesis fails if the growth portfolio cannot outrun legacy erosion, Eliquis economics weaken under Medicare pricing or competition, acquired or pipeline assets underperform, or leverage and dividends crowd out R&D flexibility.
Management
Chris Boerner and the board must prove that business development and R&D spending produce durable replacement assets, with the iberdomide and mezigdomide launches and the 2026 readouts as near-term tests.
Industry trend
Biopharma benefits from aging populations, high unmet need, and scientific progress, but the sector faces pricing scrutiny, patent cliffs, regulatory uncertainty, and binary trial outcomes.
Valuation and margin of safety
BMY trades at a reasonable forward non-GAAP earnings multiple, but the discount that existed before the earnings rally has narrowed. Margin of safety now depends on cash flow durability, replacement-product execution, and whether the market is already pricing in success.
Source-backed data
BMY Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BMY price | $65.31 at the July 31, 2026 close | StockAnalysis quote snapshot | August 2, 2026 |
| Market capitalization | $133.41 billion, verified as $65.31 x 2.043 billion shares | financial_rigor.py market cap verification | August 2, 2026 |
| Q2 2026 revenue | $12.973 billion, up 6% reported and 5% Ex-FX | BMS Q2 2026 earnings release (8-K Exhibit 99.1) | August 2, 2026 |
| Q2 2026 non-GAAP EPS | $2.04, up 40% from $1.46 | BMS Q2 2026 earnings release | August 2, 2026 |
| H1 2026 revenue | $24.462 billion, up 3% Ex-FX | BMS Q2 2026 earnings release | August 2, 2026 |
| 2026 guidance (raised) | about $49.0 billion to $50.0 billion revenue; $6.75 to $7.00 non-GAAP diluted EPS | BMS Q2 2026 earnings release | August 2, 2026 |
| Growth portfolio revenue | $7.560 billion in Q2 2026, up 14% Ex-FX, about 58% of total revenue | BMS Q2 2026 earnings release | August 2, 2026 |
| Eliquis Q2 2026 revenue | $4.481 billion, up 21% Ex-FX | BMS Q2 2026 earnings release | August 2, 2026 |
| Net debt and cash | $31.656 billion net debt and $11.464 billion cash and securities at June 30, 2026 | BMS Q2 2026 earnings release net debt table | August 2, 2026 |
| Valuation check | 9.5x 2026 guidance midpoint EPS, 11.66x FCF, 3.86% dividend yield | financial_rigor.py valuation verification | August 2, 2026 |
| Technical snapshot | 50-day SMA $58.12, 200-day SMA $55.57, 14-day RSI 71.01, 52-week high $65.66 | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Hold rating, average price target $64.91, range $40 to $80 | S&P Global via StockAnalysis forecast | August 2, 2026 |
Frequently Asked Questions
Read the ABBV AI stock analysisView MRK AI stock forecastExplore PFE AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This BMY AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory events, patent changes, market moves, or macro conditions.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Open
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Open
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Open